{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T17:02:13Z","timestamp":1776186133302,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["25K18652"],"award-info":[{"award-number":["25K18652"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["25K13462"],"award-info":[{"award-number":["25K13462"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Cefazolin is being increasingly used to treat central nervous system infections caused by methicillin-susceptible Staphylococcus aureus (MSSA) to mitigate the side effects of existing anti-Staphylococcal drugs. This study aims to develop a cerebrospinal pharmacokinetic (PK) model to predict the cefazolin concentration in cerebrospinal fluid (CSF) and to individualize the dosing regimen for MSSA meningitis. Methods: A cerebrospinal PK model was developed based on the existing literature and used to estimate the probability of attaining PK\/ pharmacodynamic (PD) targets. These targets were set as 100% time above the minimum inhibitory concentration (T &gt; MIC) in CSF. The cerebrospinal PK\/PD breakpoint was defined as the highest MIC at which target attainment probability in CSF was \u226590%. The mean CSF\/serum ratio estimated from the literature was 0.0525 after a dose of 1\u20133 g (sampling time: 1\u20139 h after dose) in adult patients with suspected meningitis. This ratio was incorporated into this PK model based on a hybrid approach. Results: For patients with creatinine clearance (CLcr) = 90 mL\/min, the cerebrospinal PK\/PD breakpoint MICs of continuous infusion regimens (6\u201312 g\/day) reached 0.5 \u00b5g\/mL, which can inhibit the growth of 90% of the MSSA population (MIC90). Furthermore, for patients with renal dysfunction (CLcr = 30 mL\/min), a dose reduction (4 g\/day) may be required to avoid excessive drug exposure. Conclusions: High-dose continuous infusion of cefazolin may be appropriate for MSSA meningitis in patients with normal renal function, while dose adjustments are needed for those with renal impairment.<\/jats:p>","DOI":"10.3390\/antibiotics14101008","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:10:31Z","timestamp":1760343031000},"page":"1008","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cerebrospinal Pharmacokinetic Modeling and Pharmacodynamic Simulation of High-Dose Cefazolin for Meningitis Caused by Methicillin-Susceptible Staphylococcus aureus"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-0787","authenticated-orcid":false,"given":"Tetsushu","family":"Onita","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, 89-1 Enya-cho, Izumo 693-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9349-4067","authenticated-orcid":false,"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-3929","authenticated-orcid":false,"given":"Noriyuki","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, 89-1 Enya-cho, Izumo 693-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, 89-1 Enya-cho, Izumo 693-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3385-6126","authenticated-orcid":false,"given":"Takahisa","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, 89-1 Enya-cho, Izumo 693-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"ref_1","unstructured":"Gilbert, D.N., Chambers, H.F., Saag, M.S., Pavia, A.T., and Boucher, H.W. (2021). The Sanford Guide to Antimicrobial Therapy, Sanford Guide. [51st ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/cid\/ciw861","article-title":"2017 Infectious Diseases Society of America\u2019s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis","volume":"64","author":"Tunkel","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","unstructured":"(2007). Nafcillin, Baxter Healthcare Corporation. Package Insert."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1128\/AAC.02800-14","article-title":"Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cmi.2017.07.003","article-title":"Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: A narrative review","volume":"24","author":"Loubet","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-018-3418-9","article-title":"Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: A systematic review and meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia","volume":"25","author":"Weis","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/AAC.10.3.395","article-title":"Pharmacological study of cefazolin during intermittent and continuous infusion: A crossover investigation in humans","volume":"10","author":"Thys","year":"1976","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01844-18","DOI":"10.1128\/AAC.01844-18","article-title":"High-Dosage Cefazolin Achieves Sufficient Cerebrospinal Diffusion to Treat an External Ventricular Drainage-Related Staphylococcus aureus Ventriculitis","volume":"63","author":"Gaborit","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1415.e1","DOI":"10.1016\/j.cmi.2020.04.046","article-title":"NAMAP study group. Should we reconsider cefazolin for treating staphylococcal meningitis? A retrospective analysis of cefazolin and cloxacillin cerebrospinal fluid levels in patients treated for staphylococcal meningitis","volume":"26","author":"Gregoire","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ofab649","DOI":"10.1093\/ofid\/ofab649","article-title":"Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically Ill Patients","volume":"9","author":"Novak","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/phar.2750","article-title":"Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation","volume":"43","author":"Antosz","year":"2023","journal-title":"Pharmacotherapy"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Onita, T., Ishihara, N., and Yano, T. (2025). PK\/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance. Antibiotics, 14.","DOI":"10.3390\/antibiotics14010092"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1086\/321854","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","first-page":"457","article-title":"Penetration of cefazolin into cerebrospinal fluid and brain tissue","volume":"14","author":"Ikuno","year":"1977","journal-title":"Med. Consult. New Remedies"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e0185724","DOI":"10.1128\/aac.01857-24","article-title":"Optimizing cefazolin dosing for central nervous system infections: Insights from population pharmacokinetics and Monte Carlo simulations","volume":"69","author":"Pitcock","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","first-page":"271","article-title":"Seizures associated with high cerebrospinal fluid concentrations of cefazolin","volume":"37","author":"Bechtel","year":"1980","journal-title":"Am. J. Hosp. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijantimicag.2019.06.021","article-title":"Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis","volume":"54","author":"Ohata","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jcph.1800","article-title":"Prostatic Pharmacokinetic\/Pharmacodynamic Evaluation of Ampicillin-Sulbactam for Bacterial Prostatitis and Preoperative Prophylaxis","volume":"61","author":"Onita","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Onita, T., Ikawa, K., Ishihara, N., Tamaki, H., Yano, T., Naora, K., and Morikawa, N. (2023). Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin\/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including Acinetobacter baumannii. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020303"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/jcph.6119","article-title":"Prostatic Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime: Dosing Strategy for Bacterial Prostatitis","volume":"65","author":"Onita","year":"2025","journal-title":"J. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"19763","DOI":"10.1038\/s41598-021-99162-7","article-title":"Population pharmacokinetic model of cefazolin in total hip arthroplasty","volume":"11","author":"Chaux","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/brain\/91.4.707","article-title":"Formation and absorption of cerebrospinal fluid in man","volume":"91","author":"Cutler","year":"1968","journal-title":"Brain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10928-020-09695-z","article-title":"Prior information for population pharmacokinetic and pharmacokinetic\/pharmacodynamic analysis: Overview and guidance with a focus on the NONMEM PRIOR subroutine","volume":"47","author":"Calvier","year":"2020","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-200645020-00004","article-title":"Role of mechanistically-based pharmacokinetic\/pharmacodynamic models in drug development: A case study of a therapeutic protein","volume":"45","author":"Marshall","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)\u2014A Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput. Methods Programs Biomed."},{"key":"ref_30","unstructured":"(2025, February 12). Four Academic Societies Joint Antimicrobial Susceptibility Surveillance Program. Available online: https:\/\/www.3ssp.jp\/database\/surgical\/mic-5090\/."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/10\/1008\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:56:30Z","timestamp":1760345790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/10\/1008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["antibiotics14101008"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14101008","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]}}}